Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

14.81 +0.59 (+4.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,800,843
Open 14.21
Bid (Size) 14.50 (2)
Ask (Size) 14.82 (2)
Prev. Close 14.22
Today's Range 14.01 - 14.85
52wk Range 13.95 - 34.87
Shares Outstanding 88,140,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking Into Intellia Therapeutics's Recent Short Interest
Via Benzinga
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool

Performance

YTD
-51.95%
-51.95%
1 Month
-16.09%
-16.09%
3 Month
-33.68%
-33.68%
6 Month
-37.56%
-37.56%
1 Year
-48.50%
-48.50%

More News

Read More
7 Analysts Have This To Say About Intellia Therapeutics
Via Benzinga
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Why Intellia Therapeutics Stock Plummeted by 20% Today
Via The Motley Fool
A Closer Look at Intellia Therapeutics's Options Market Dynamics
Via Benzinga
3 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Via Benzinga
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
Via Benzinga
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Via The Motley Fool
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street
Via The Motley Fool
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Via The Motley Fool
Expert Ratings For Intellia Therapeutics
Via Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
Via InvestorPlace
NTLA Stock Earnings: Intellia Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
7 Biotech Stocks to Keep on Your Clinical Radar
Via InvestorPlace
3 Gene Editing Stocks That Could Grow Your Wealth
Via InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Via Benzinga
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Via InvestorPlace
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Via The Motley Fool
The 3 Best Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.